Overview

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Kala Pharmaceuticals, Inc.
Treatments:
Loteprednol Etabonate